News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Ark Therapeutics to License Out Heart Attack Risk Kit Marketing
October 8, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Oct 8 (Reuters) - Ark Therapeutics (AKT.L: Quote, Profile, Research) said on Monday it was to license out marketing rights for its Ox-LDL heart attack risk test kit to UK-based diagnostics company Lab21.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Europe
MORE ON THIS TOPIC
Podcast
Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More
July 9, 2025
·
1 min read
·
Heather McKenzie
Radiopharmaceuticals
Actithera Raises $75.5M To Play in Sizzling Radiopharma Space
July 9, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Concentra Snags Another Struggling Biotech as Cargo Accepts $200M Buyout
July 8, 2025
·
1 min read
·
Annalee Armstrong
Artificial intelligence
Roche’s Chugai Breaks Into Aging via Potential $1B+ Deal With AI Outfit Gero
July 7, 2025
·
2 min read
·
Dan Samorodnitsky
